MTOR and Hyperglycemia: At the 3125 mg BID MTD dose, patients did not experience adverse reactions typically associated with either cytotoxic chemotherapy, tyrosine kinase inhibitors, or the Akt/mTOR pathway (such as rash, mucositis and hyperglycemia), nor did they experience significant diarrhea as has been reported with nelfinavir in HIV patients.